What is Bridgebio Pharma?
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, creating, testing, and delivering innovative therapies for patients suffering from rare genetic diseases and cancers. The company's pipeline includes promising drug candidates such as AG10, a Phase 3 oral small molecule TTR stabilizer for TTR amyloidosis; low-dose infigratinib, an investigational FGFR1-3 selective tyrosine kinase inhibitor in Phase 3 trials for achondroplasia in children; and BBP-631, an AAV5 gene transfer candidate in Phase 1/2 trials for congenital adrenal hyperplasia. The company's strategic focus on genetically defined diseases positions it at the forefront of precision medicine.
How much funding has Bridgebio Pharma raised?
Bridgebio Pharma has raised a total of $3B across 7 funding rounds:
Multiple Rounds
$174.7M
Other Financing Round
$299.2M
Debt
$475M
Debt
$750M
Other Financing Round
$300M
Series B (2017): $33.1M with participation from Neil Kumar and KKR
Series A (2017): $6.6M, investors not publicly disclosed
Series C (2017): $135M supported by Perceptive Advisors, Aisling Capital, and Cormorant Asset Management
Other Financing Round (2019): $299.2M featuring Hercules Capital, Aisling Capital, AIG, Cormorant Capital, Perceptive Advisors, and Steamboat Ventures
Debt (2020): $475M, investors not publicly disclosed
Debt (2021): $750M, investors not publicly disclosed
Other Financing Round (2025): $300M led by Blue Owl and HealthCare Royalty Management
Key Investors in Bridgebio Pharma
Hercules Capital
Hercules Capital is a specialty finance company providing senior secured venture growth loans to innovative, venture capital-backed companies in technology and life sciences. They are headquartered in Palo Alto, California.
Aisling Capital
Aisling Capital is a leading investment firm specializing in innovative healthcare products and technologies, with a focus on biopharmaceutical development and commercial outsourcing for areas like genomically defined cancers and neuroscience.
Perceptive Advisors
Perceptive Advisors is an investment firm based in New York, NY, managing significant assets focused on funding innovative healthcare and life sciences technologies.
What's next for Bridgebio Pharma?
The substantial capital infusion, characterized as a major enterprise-level funding and a major strategic investment, indicates BridgeBio Pharma is poised for significant scaling and advancement of its clinical pipeline. This financing will likely accelerate the development and potential commercialization of its lead drug candidates, particularly AG10 and infigratinib, and further bolster its research into novel gene therapies. The company's trajectory suggests a strong emphasis on navigating late-stage clinical trials and preparing for market entry, reinforcing its commitment to addressing unmet needs in genetic disease and oncology.
See full Bridgebio Pharma company page
